Citation tools
"Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study." Journal of Nuclear Medicine
64.4
(2023):
574-578.
Web. 10 Oct. 2024.